Atorvo+™
Atorvo+ Development
Pfizer’s Lipitor® (Atorvastatin) was the best-selling pharmaceutical of all time totaling well over $125 billion in sales, prior to becoming generic. Even today, Atorvastatin represents almost half of the estimated $22 billion statin market in the United States.1
Indication BioScience’s Atorva+ formulation combines an FDA-approved small molecule with Atorvastatin, with an opportunity to create a new improved fixed-dose combination that may have advantages for patients. Indication BioScience also intends to develop additional combination statins including Rosuvastatin, Simvastatin, and Lovastatin.
- 1. JAMA Network Open. 2021;4(11):e2135371. doi:10.1001/jamanetworkopen.2021.35371
Pre-Clinical
At Indication Bioscience, our pre-clinical research lays the foundation for transformative therapies. By combining rigorous scientific methods with innovative technologies, we evaluate the safety, efficacy, and unique advantages of our drug candidates before advancing to clinical trials. Our lead program, Atorvo+, has demonstrated compelling pre-clinical data, showcasing its potential to address statin intolerance while maintaining effective cholesterol management. These findings reinforce our commitment to advancing therapies that solve real-world challenges and improve patient outcomes.
Accelerated Pathway
At Indication Bioscience, we are harnessing an accelerated development pathway to bring innovative therapies to patients faster. By leveraging existing safety and efficacy data from established compounds, we reduce the time and cost typically associated with drug development. This streamlined approach allows us to focus on addressing critical unmet needs, such as improving statin adherence and reducing treatment side effects. Our accelerated pathway ensures we can deliver safe, effective, and transformative solutions to patients without unnecessary delays.